Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is thought to reduce elevated ammonia levels in the blood by promoting its detoxification in the liver and kidneys.
## Primary Indications
Hepatic encephalopathy (grades I-III) in patients with cirrhosis.
## Adult Dosing
* **Initial:** 3 to 6 grams intravenously (IV) every 8 hours.
* **Maximum:** Typically no more than 18 grams per day.
* **Oral (if available):** Dosing varies by product formulation and country. Commonly, 3-6 grams orally up to three times daily. Consult specific product labeling for oral dosage.
## Pediatric Dosing
Data regarding the safety and efficacy of Hepamerz in pediatric patients is limited. Dosing should be determined by a specialist based on the individual patient's condition and response.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is intended for patients with liver disease. However, caution and close monitoring are advised.
## Contraindications
* Severe renal insufficiency (serum creatinine >3 mg/dL).
* Known hypersensitivity to l-ornithine or l-aspartate.
## Adverse Effects
Common adverse effects include nausea, vomiting, abdominal discomfort, and diarrhea. Less common effects may include headache, dizziness, and allergic reactions.
## Key Drug Interactions
No significant drug interactions have been definitively established. However, due to its use in patients with liver disease, caution should be exercised with other hepatically metabolized drugs.
## Monitoring
* Monitor serum ammonia levels.
* Assess neurological status for improvement or deterioration.
* Monitor electrolytes and renal function.
## Clinical Pearls
* The IV formulation is generally used for more acute presentations or when oral intake is compromised.
* Treatment duration depends on clinical response and severity of hepatic encephalopathy.
* Effectiveness is primarily observed in patients with cirrhosis and hyperammonemia.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines before administering any medication. Dosing and indications may vary based on local protocols and specific product labeling.*
